Literature DB >> 18184970

Diagnostic potential of serum VEGF-D for lymphangioleiomyomatosis.

Lisa R Young, Yoshikazu Inoue, Francis X McCormack.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18184970      PMCID： PMC3804557          DOI： 10.1056/NEJMc0707517

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  5 in total

Review 1.  The tuberous sclerosis complex.

Authors:  Peter B Crino; Katherine L Nathanson; Elizabeth Petri Henske
Journal:  N Engl J Med       Date:  2006-09-28       Impact factor: 91.245

2.  Vascular endothelial growth factor-D is increased in serum of patients with lymphangioleiomyomatosis.

Authors:  Kuniaki Seyama; Toshio Kumasaka; Sanae Souma; Teruhiko Sato; Masatoshi Kurihara; Keiko Mitani; Sigeru Tominaga; Yoshinosuke Fukuchi
Journal:  Lymphat Res Biol       Date:  2006       Impact factor: 2.589

Review 3.  Lymphangioleiomyomatosis.

Authors:  S R Johnson
Journal:  Eur Respir J       Date:  2006-05       Impact factor: 16.671

4.  Chronic cystic lung disease: diagnostic accuracy of high-resolution CT in 92 patients.

Authors:  Mitsuhiro Koyama; Takeshi Johkoh; Osamu Honda; Mitsuko Tsubamoto; Takenori Kozuka; Noriyuki Tomiyama; Seiki Hamada; Hironobu Nakamura; Masanori Akira; Kazuya Ichikado; Kiminori Fujimoto; Toru Rikimaru; Ukihide Tateishi; Nestor L Müller
Journal:  AJR Am J Roentgenol       Date:  2003-03       Impact factor: 3.959

Review 5.  Molecular pathogenesis of lymphangioleiomyomatosis: lessons learned from orphans.

Authors:  Stephen C Juvet; Francis X McCormack; David J Kwiatkowski; Gregory P Downey
Journal:  Am J Respir Cell Mol Biol       Date:  2006-11-10       Impact factor: 6.914
  5 in total
  54 in total

1.  Concentration of Serum Vascular Endothelial Growth Factor (VEGF-D) and Its Correlation with Functional and Clinical Parameters in Patients with Lymphangioleiomyomatosis from a Brazilian Reference Center.

Authors:  Alexandre Franco Amaral; Martina Rodrigues de Oliveira; Olívia Meira Dias; Fábio Eiji Arimura; Carolina Salim Gonçalves Freitas; Milena Marques Pagliarelli Acencio; Vanessa Adélia de Alvarenga; Ronaldo Adib Kairalla; Carlos Roberto Ribeiro Carvalho; Bruno Guedes Baldi
Journal:  Lung       Date:  2019-01-08       Impact factor: 2.584

Review 2.  The Lymphangioleiomyomatosis Lung Cell and Its Human Cell Models.

Authors:  Wendy K Steagall; Gustavo Pacheco-Rodriguez; Thomas N Darling; Olga Torre; Sergio Harari; Joel Moss
Journal:  Am J Respir Cell Mol Biol       Date:  2018-06       Impact factor: 6.914

3.  Enhanced epidermal growth factor, hepatocyte growth factor, and vascular endothelial growth factor expression in tuberous sclerosis complex.

Authors:  Whitney E Parker; Ksenia A Orlova; Gregory G Heuer; Marianna Baybis; Eleonora Aronica; Michael Frost; Michael Wong; Peter B Crino
Journal:  Am J Pathol       Date:  2010-12-23       Impact factor: 4.307

Review 4.  Diffuse Cystic Lung Disease. Part I.

Authors:  Nishant Gupta; Robert Vassallo; Kathryn A Wikenheiser-Brokamp; Francis X McCormack
Journal:  Am J Respir Crit Care Med       Date:  2015-06-15       Impact factor: 21.405

5.  Apparent Sporadic Lymphangioleiomyomatosis in a Man as a Result of Extreme Mosaicism for a TSC2 Mutation.

Authors:  MeiLan K Han; Magdalena E Tyburczy; Thomas N Darling; Ella A Kazerooni; Jeffrey L Myers; Francis X McCormack; Joel Moss; David J Kwiatkowski
Journal:  Ann Am Thorac Soc       Date:  2017-07

6.  Prevention of alveolar destruction and airspace enlargement in a mouse model of pulmonary lymphangioleiomyomatosis (LAM).

Authors:  Elena A Goncharova; Dmitry A Goncharov; Melane Fehrenbach; Irene Khavin; Blerina Ducka; Okio Hino; Thomas V Colby; Mervyn J Merrilees; Angela Haczku; Steven M Albelda; Vera P Krymskaya
Journal:  Sci Transl Med       Date:  2012-10-03       Impact factor: 17.956

7.  Circulating Biomarkers From the Phase 1 Trial of Sirolimus and Autophagy Inhibition for Patients With Lymphangioleiomyomatosis.

Authors:  Anthony M Lamattina; Angelo Taveira-Dasilva; Hilary J Goldberg; Shefali Bagwe; Ye Cui; Ivan O Rosas; Joel Moss; Elizabeth P Henske; Souheil El-Chemaly
Journal:  Chest       Date:  2018-08-23       Impact factor: 9.410

8.  Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guidelines: Lymphangioleiomyomatosis Diagnosis and Management.

Authors:  Francis X McCormack; Nishant Gupta; Geraldine R Finlay; Lisa R Young; Angelo M Taveira-DaSilva; Connie G Glasgow; Wendy K Steagall; Simon R Johnson; Steven A Sahn; Jay H Ryu; Charlie Strange; Kuniaki Seyama; Eugene J Sullivan; Robert M Kotloff; Gregory P Downey; Jeffrey T Chapman; MeiLan K Han; Jeanine M D'Armiento; Yoshikazu Inoue; Elizabeth P Henske; John J Bissler; Thomas V Colby; Brent W Kinder; Kathryn A Wikenheiser-Brokamp; Kevin K Brown; Jean F Cordier; Cristopher Meyer; Vincent Cottin; Jan L Brozek; Karen Smith; Kevin C Wilson; Joel Moss
Journal:  Am J Respir Crit Care Med       Date:  2016-09-15       Impact factor: 21.405

9.  Comparison of three rapamycin dosing schedules in A/J Tsc2+/- mice and improved survival with angiogenesis inhibitor or asparaginase treatment in mice with subcutaneous tuberous sclerosis related tumors.

Authors:  Chelsey Woodrum; Alison Nobil; Sandra L Dabora
Journal:  J Transl Med       Date:  2010-02-10       Impact factor: 5.531

10.  Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models.

Authors:  Nancy Lee; Chelsey L Woodrum; Alison M Nobil; Aubrey E Rauktys; Michael P Messina; Sandra L Dabora
Journal:  BMC Pharmacol       Date:  2009-04-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.